Communications Medicine (May 2022)

Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy

  • Jennifer M. Knight,
  • Aniko Szabo,
  • Igli Arapi,
  • Ruizhe Wu,
  • Amanda Emmrich,
  • Edward Hackett,
  • Garrett Sauber,
  • Sharon Yim,
  • Bryon Johnson,
  • Parameswaran Hari,
  • Dina Schneider,
  • Boro Dropulic,
  • Rachel N. Cusatis,
  • Steve W. Cole,
  • Cecilia J. Hillard,
  • Nirav N. Shah

DOI
https://doi.org/10.1038/s43856-022-00116-5
Journal volume & issue
Vol. 2, no. 1
pp. 1 – 10

Abstract

Read online

Knight et al. assess short-term patient-reported outcomes (PROs) and markers of neurotoxicity in patients with leukaemia or lymphoma treated with LV20.19 CAR T cells. In this small trial cohort, the authors report improvements in mood following CAR T infusion and identify kynurenine pathway molecules as potential markers of mood and neurotoxicity.